You are here

Multifunctional Integrated Photonic Lab-on-a-Chip for Astronaut Health Monitoring

Award Information
Agency: National Aeronautics and Space Administration
Branch: N/A
Contract: 80NSSC19C0016
Agency Tracking Number: 170069
Amount: $749,836.00
Phase: Phase II
Program: STTR
Solicitation Topic Code: T8
Solicitation Number: STTR_17_P2
Timeline
Solicitation Year: 2017
Award Year: 2019
Award Start Date (Proposal Award Date): 2019-03-05
Award End Date (Contract End Date): 2021-09-03
Small Business Information
2363 Calle Del Mundo
Santa Clara, CA 95054-1008
United States
DUNS: 877452664
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Behzad Moslehi
 (408) 565-9004
 bm@ifos.com
Business Contact
 Behzad Moslehi
Phone: (408) 565-9004
Email: bm@ifos.com
Research Institution
 Stanford University
 
450 Serra Mall
Stanford, CA 00000-0000
United States

 Federally funded R&D center (FFRDC)
Abstract

IFOS is developing a multifunctional whole-blood analysis lab-on-a-chip platform for assessment of kidney health. The IFOS innovations are found in each subsystem, including photonic integrated circuits (PICs), microelectronics, and biochemical microfluidics. The unique differentiated design is expected to result in a low SWaP-C, highly manufacturable, and highly reliable on-demand measurement platform for diverse medical applications both on earth and during space missions. In Phase 1, the IFOS multidisciplinary team ndash; including Stanfordrsquo;s medical and engineering departments ndash; demonstrated the feasibility of IFOSrsquo; innovative PIC-based platform. The team not only accomplished all technical objectives but went beyond with an in-depth exploration of the commercial potential and end use of the IFOS innovations through direct interaction with over 100 potential customers and users. This is expected to significantly enhance and accelerate the go-to-market process. Phase 2 builds on the solid technical and commercial foundations to complete the Ramp;D and transform the feasibility results into a portable, multifunctional, reliable and commercially viable product (Bio*Sensetrade;) ready for production. IFOSrsquo; team of medical experts and advisors will accelerate the regulatory and go-to-market processes. Strong evidence of commercial viability is indicated by the endorsement of medical community experts and attainment of investment commitment for Phasesnbsp;2/3.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government